TATAA Biocenter AB announces new leadership team to support long-term ambitions.

TATAA Biocenter AB (the “Company” or “TATAA”), a leading global CRO for high-quality molecular analysis, today announces a new leadership team to support the Company’s continued growth and long-term ambitions.

The new appointments include Mathias Hallin to the role of Chief Executive Officer, Kennet Mattsson to the role of SVP of Commercial Operations, and Kristofer Hellberg to the role of SVP of Laboratory Services.

These appointments will allow TATAA to continue its mission of providing bespoke discovery services and regulated molecular analysis to the biopharmaceutical industry while further investing in research and development, enhancing its services offering, and maintaining its position as a trusted CRO partner to clients.

Contact for more info:
Martin Cooke, TATAA Biocenter, Marketing & Comms Specialist.
Email: martin.cooke@tataa.com
 

TATAA Biocenter is leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and the Cell and Gene Therapy in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices (GLP/GCP) TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling including genomics, transcriptomics, proteomics and microbiomics with traditional qPCR, dPCR and NGS methods as well as proprietary methods.